Lindsey Shapiro, PhD, science writer —

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

Altered Blood Vessel Repair Process ID’d in GPA Remission Patients

The function of endothelial colony-forming cells (ECFCs) is impaired in people with granulomatosis with polyangiitis (GPA) — a type of ANCA-associated vasculitis (AAV) — who are in disease remission, according to a recent study. Impairments in ECFCs’ ability to repair damaged blood vessels — their normal role — even…

Immune Checkpoint Molecules Linked to Risk of Relapse in AAV

Blood levels of molecules called soluble immune checkpoints (sICPs) may serve as biomarkers of relapse risk in people with ANCA-associated vasculitis (AAV), a study found. Patients with lower levels of these molecules were more likely to relapse after being in remission following treatment with rituximab, but were less likely…

Blocking Immune Molecule IL-21 May Be Target as MPO-AAV Therapy

Levels of the immune signaling molecule interleukin-21 (IL-21) and the cells that produce the protein were elevated in the blood of people with ANCA-associated vasculitis (AAV) with myeloperoxidase (MPO) antibodies, a study found. IL-21 levels also were linked to higher MPO levels and disease activity, suggesting its direct involvement in…

AAV Emerges in Boy Using Levamisole to Treat Kidney Disease

ANCA-associated vasculitis (AAV) emerged as a side effect of levamisole given for years to treat a 15-year-old boy with idiopathic nephrotic syndrome, according to a case report. “By reporting this case, we want to raise awareness among clinicians regarding a rare complication of treatment with Levamisole that is often…

Lung, ENT Involvement, Steroid Use Reduced With Tavneos: ADVOCATE

Tavneos (avacopan) reduced respiratory, ear, nose, and throat (ENT) involvement among people with ANCA-associated vasculitis (AAV), but did not significantly outperform prednisone in its ability to do so, according to a substudy of the larger Phase 3 ADVOCATE trial. The treatment also significantly lowered patients’ reliance on glucocorticoid…